Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (12,310,287)	$ (7,613,777)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock based compensation	1,770,950	721,200
Depreciation and amortization	5,980
Changes in operating assets and liabilities:
Receivable due from collaboration agreement	(489,221)
Research and development tax incentive receivable	(958,363)
Prepaid assets and other current assets	285,090	491,273
Accounts payable	213,399	274,255
Deferred revenue	685
Net cash used in operating activities	(11,481,767)	(6,127,049)
Cash flows from investing activities:
Purchases of property and equipment	(600,210)
Net cash used in investing activities	(600,210)
Cash flows from financing activities:
Net proceeds from issuance of common stock	28,015,019
Proceeds from issuance of common stock for stock option exercises	689,753
Proceeds from issuance of common stock for warrant exercises	180,212
Net cash provided by financing activities	28,884,984
Effect of exchange rate changes on cash and cash equivalents	(36,473)	(43,768)
Net change in cash and cash equivalents	16,766,534	(6,170,817)
Cash and cash equivalents at beginning of period	35,300,805	28,094,936
Cash and cash equivalents at end of period	52,067,339	21,924,119
Supplemental disclosure of non-cash investing and financing activities:
Issuance of common stock for accrued research and development expense		1,132,013
Cashless exercise of warrants	$ 416